Routine-Data Triage for MASLD Positive on Vibration-Controlled Transient Elastography after FIB-4: An Exploratory NHANES Pathway Comparison Study with Temporal Validation.

IF 4.1 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Gut and Liver Pub Date : 2026-09-22 DOI:10.5009/gnl260210
Wenbin Jiang, Yao Ge, Yihan Chai, Kexin Jiang, Qijiang Mao
{"title":"Routine-Data Triage for MASLD Positive on Vibration-Controlled Transient Elastography after FIB-4: An Exploratory NHANES Pathway Comparison Study with Temporal Validation.","authors":"Wenbin Jiang, Yao Ge, Yihan Chai, Kexin Jiang, Qijiang Mao","doi":"10.5009/gnl260210","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aims: </strong>Contemporary metabolic dysfunction-associated steatotic liver disease (MASLD) pathways use the fibrosis-4 index (FIB-4) before vibration-controlled transient elastography (VCTE), but FIB-4-based rules may miss adults with VCTE-defined increased liver stiffness. We quantified VCTE-positive burden across low-risk and indeterminate FIB-4 groups and evaluated an exploratory routine-data second-stage triage strategy in the National Health and Nutrition Examination Survey (NHANES).</p><p><strong>Methods: </strong>Adults with MASLD from NHANES 2017 to March 2020 formed the development cohort, and those from August 2021 to August 2023 formed the temporal validation cohort. MASLD required controlled attenuation parameter-defined steatosis, cardiometabolic risk, and exclusion of significant alcohol use and viral hepatitis. The primary endpoint was liver stiffness measurement (LSM) ≥8 kPa; LSM thresholds of 7, 10, and 12 kPa were tested. A regularized logistic model was developed among adults with FIB-4 ≤2.67. The enhanced hybrid pathway referred adults with FIB-4 >2.67 or, among those with FIB-4 ≤2.67, model probability ≥0.159561.</p><p><strong>Results: </strong>The development cohort included 3,004 adults, 503 (16.7%) with LSM ≥8 kPa; validation included 1,959 adults, 408 (20.8%) with LSM ≥8 kPa. In validation, LSM ≥8 kPa occurred in 221/1,228 with FIB-4 <1.3 and 111/473 with FIB-4 1.3 to 2.67. Standard FIB-4 referral detected 137/408 cases while referring 528 of 1,959 adults; the enhanced pathway detected 233 of 408 while referring 621 of 1,959. In low/intermediate FIB-4 validation adults, the model area under the receiver operating characteristic curve was 0.742.</p><p><strong>Conclusions: </strong>Low-risk and indeterminate FIB-4 groups contained substantial VCTE-positive burden. This exploratory enhanced pathway identified more VCTE-positive adults with modestly higher referral burden, supporting prospective validation.</p>","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gut and Liver","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5009/gnl260210","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aims: Contemporary metabolic dysfunction-associated steatotic liver disease (MASLD) pathways use the fibrosis-4 index (FIB-4) before vibration-controlled transient elastography (VCTE), but FIB-4-based rules may miss adults with VCTE-defined increased liver stiffness. We quantified VCTE-positive burden across low-risk and indeterminate FIB-4 groups and evaluated an exploratory routine-data second-stage triage strategy in the National Health and Nutrition Examination Survey (NHANES).

Methods: Adults with MASLD from NHANES 2017 to March 2020 formed the development cohort, and those from August 2021 to August 2023 formed the temporal validation cohort. MASLD required controlled attenuation parameter-defined steatosis, cardiometabolic risk, and exclusion of significant alcohol use and viral hepatitis. The primary endpoint was liver stiffness measurement (LSM) ≥8 kPa; LSM thresholds of 7, 10, and 12 kPa were tested. A regularized logistic model was developed among adults with FIB-4 ≤2.67. The enhanced hybrid pathway referred adults with FIB-4 >2.67 or, among those with FIB-4 ≤2.67, model probability ≥0.159561.

Results: The development cohort included 3,004 adults, 503 (16.7%) with LSM ≥8 kPa; validation included 1,959 adults, 408 (20.8%) with LSM ≥8 kPa. In validation, LSM ≥8 kPa occurred in 221/1,228 with FIB-4 <1.3 and 111/473 with FIB-4 1.3 to 2.67. Standard FIB-4 referral detected 137/408 cases while referring 528 of 1,959 adults; the enhanced pathway detected 233 of 408 while referring 621 of 1,959. In low/intermediate FIB-4 validation adults, the model area under the receiver operating characteristic curve was 0.742.

Conclusions: Low-risk and indeterminate FIB-4 groups contained substantial VCTE-positive burden. This exploratory enhanced pathway identified more VCTE-positive adults with modestly higher referral burden, supporting prospective validation.

FIB-4后振动控制瞬态弹性成像中MASLD阳性的常规数据分类:具有时间验证的探索性NHANES路径比较研究。
背景/目的:当代代谢功能障碍相关脂肪变性肝病(MASLD)途径在振动控制瞬时弹性成像(VCTE)之前使用纤维化-4指数(FIB-4),但基于FIB-4的规则可能会忽略VCTE定义的肝脏硬度增加的成人。我们量化了低风险和不确定FIB-4组的vcte阳性负担,并在国家健康和营养检查调查(NHANES)中评估了探索性常规数据第二阶段分诊策略。方法:NHANES 2017年至2020年3月期间的成人MASLD患者组成发展队列,2021年8月至2023年8月期间的成人MASLD患者组成时间验证队列。MASLD需要控制衰减参数定义的脂肪变性、心脏代谢风险,并排除严重的酒精使用和病毒性肝炎。主要终点为肝硬度测量(LSM)≥8 kPa;分别检测7、10、12 kPa的LSM阈值。在FIB-4≤2.67的成人中建立了正则化logistic模型。增强杂交途径涉及FIB-4 >2.67的成人,或FIB-4≤2.67的成人模型概率≥0.159561。结果:发展队列包括3,004名成人,其中LSM≥8 kPa的503名(16.7%);验证纳入成人1959例,LSM≥8kpa 408例(20.8%)。在验证中,221/ 1228例FIB-4患者发生LSM≥8kpa。结论:低风险和不确定FIB-4组含有大量的vcte阳性负担。这一探索性增强途径确定了更多的vcte阳性成人,转诊负担略高,支持前瞻性验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gut and Liver
Gut and Liver 医学-胃肠肝病学
CiteScore
7.50
自引率
8.80%
发文量
119
审稿时长
6-12 weeks
期刊介绍: Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut and Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. Gut and Liver is jointly owned and operated by 8 affiliated societies in the field of gastroenterology, namely: the Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, the Korean College of Helicobacter and Upper Gastrointestinal Research, the Korean Association for the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, the Korean Pancreatobiliary Association, and the Korean Society of Gastrointestinal Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书